Section Arrow
Quote
ZNTL.NASDAQ
- Zentalis Pharmaceuticals
(Financial Status)
Quotes are at least 15-min delayed:2024/05/04 20:58 EDT
Last
 11.71
+0.6 (+5.40%)
Day High 
12.11 
Prev. Close
11.11 
1-M High
16.21 
Volume 
498.08K 
Bid
11.68
Ask
12.5
Day Low
11.44 
Open
11.63 
1-M Low
10.39 
Market Cap 
788.96M 
Currency USD 
P/E -- 
%Yield 0 
10-SMA 11.72 
20-SMA 12.78 
50-SMA 13.86 
52-W High 31.46 
52-W Low 9.56 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.47/-4.03
Enterprise Value
832.11M
Balance Sheet
Book Value Per Share
6.16
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
JAGXJaguar Health0.318+0.0248+8.46%-- 
VAXXVaxxinity0.1411+0.0369+35.41%-- 
DNAGinkgo Bioworks Holdings0.955+0.0939+10.90%-- 
ARDXArdelyx8.72+1.93+28.42%-- 
IBRXImmunityBio9.15+0.18+2.01%-- 
Quotes are at least 15-min delayed：2024/05/04 20:58 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.